Learning Objectives
- Demonstrate an increase in the learner’s knowledge of clinical medicine.
- Demonstrate an improvement in the learner’s ability to make decisions that provide safe and effective medical care.
- Recognize areas of personal strength and areas for growth in clinical knowledge.
Intended Audience
Physicians and residents who are seeking to maintain and augment their knowledge in clinical medicine and/or preparing for their initial board certification or recertification.
Accreditation
The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities.
All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies.
AMA Credit Designation Statement
The Massachusetts Medical Society designates this enduring material for a maximum of 357 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 357 hours of Category 1 credit for completing this program.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 357 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College of Physicians and Surgeons of Canada
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Method of Participation
You must answer questions correctly to receive CME credit and MOC points.
Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™.
Six questions answered correctly equal 1 MOC point.
Accreditation Term:
CME credit and MOC points are available for 3 years. Term begins January 27, 2020.
Original Release Date: January 27, 2014
Review dates: 2015, 2016, 2017, 2019, 2020, 2021, 2022
Termination Date: January 27, 2024
MMS Disclosure Policy
The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities. All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies.Individual Disclosures
Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years.
Vaneeta Bamba, MD
| 2021 | Novo Nordisk, Growth Advisory Board for Genetic Short Stature, discontinued Nov 2020 |
| 2022 | Nothing disclosed |
| 2023 | Nothing disclosed |
Ethan Brown, MD
| 2021 | Rune Labs, consultant, discontinued Apr 2019 |
| 2022 | Rune Labs, consultant |
| 2023 | Nothing disclosed |
Steven Chen, MD
| 2022 | Pfizer, advisory board member, discontinued May 2021 Novartis, advisory board member, discontinued Dec 2021 |
Ezra M. Cohen, MD
| 2021 | Cornerstone Research Group, consultant |
| 2022 | Nothing disclosed |
| 2023 | Presidio, scientific board member |
Nathan Connell, MD
| 2021 | Nothing disclosed |
| 2022 | Takeda Pharmaceutical, consultant |
| 2023 | Takeda Pharmaceutical, consultant Octapharma, honoraria Genentech, advisory board member Doximity, equity |
Areeg H. El-Gharbawy, MD
| 2021 | Ultragenyx, principal investigator for a clinical trial Ultragenyx, advisory board member Amicus, advisory board member |
Rajesh T. Gandhi, MD
| 2021 | Merck, scientific advisory board |
| 2022 | Nothing disclosed |
| 2023 | Nothing disclosed |
Glenn J. Hanna, MD
| 2022 | Actuate Therapeutics, grant/funding Bicara, consultant/advisory board Bicara, grant/funding Boxer Capital, consultant Bristol Myers Squibb, grant/funding Bristol Myers Squibb, consultant Coherus, consultant Elevar, consultant/advisory board Exicure, grant/funding, discontinued Jan 2022 Exicure, consultant/advisory board Gateway for Cancer Research, grant/funding Genentech, grant/funding General Catalyst, consultant GlaxoSmithKline, grant/funding ImmunityBio, grant/funding Kartos Therapeutics, grant/funding Kite Pharma, grant/funding, discontinued Jun 2022 KSQ Therapeutics, consultant KSQ Therapeutics, grant/funding Kura Oncology, consultant/advisory board Kura Oncology, grant/funding Merck, consultant/advisory board Naveris, consultant/advisory board Prelude, consultant/advisory board Rain Therapeutics, consultant, discontinued Nov 2021 Regeneron, consultant/advisory board Regeneron, grant/funding Remix Therapeutics, consultant/advisory board Repertoire, grant/funding Sanofi Genzyme, advisory board, discontinued Nov 2021 Sanofi Genzyme, grant/funding Secura Bio, grant/funding V Foundation, grant/funding, discontinued Jun 2022 |
Jonathan S. Hausmann, MD
| 2021 | Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant |
| 2022 | Pfizer, consultant, discontinued Dec 2020 Biogen, consultant, discontinued Dec 2020 Novartis, consultant |
| 2023 | Fresenius Kabi, consultant Novartis, consultant |
Brian C. Healy, MD
| 2021 | Analysis Group, grant support |
| 2022 | Analysis Group, research support to institution, discontinued Nov 2020 |
| 2023 | Novartis, research support |
Koyal Jain, MD, MPH
| 2022 | PI for Kaneka study and Visterra study |
Mihir M. Kamdar, MD
| 2021 | Amorsa Therapeutics, scientific advisory board, stockholder Medtronic, consultant, fees Fern Health, consultant, fees |
| 2022 | Nothing disclosed |
| 2023 | Elevate, cofounder and chief medical officer Fern Health, medical advisor |
Ruslan Korets, MD
| 2021 | Boston Scientific, consultant |
| 2022 | Boston Scientific, consultant |
| 2023 | Boston Scientific, consultant |
Lekha M. Rao, MD
| 2023 | Epigenyx Therapeutics, consultant UCB, principal investigator for a clinical trial Eisai, principal investigator for a clinical trial |
Leigh C. Reardon, MD
| 2021 | Janssen, speaker |
| 2022 | Janssen, advisory committee |
| 2023 | Janssen, consultant |
Eric Roeland, MD
| 2023 | Napo Pharmaceuticals, scientific advisory board Actimed Therapeutics, scientific advisory board Meter Health, scientific advisory board Veloxis Pharmaceuticals, consultant Aileron Therapeutics, consultant BYOMass, consultant Takeda, advisory board Enzychem Lifesciences Pharmaceutical Company, data safety monitoring board |
Deborah R. Stein, MD
| 2021 | Nothing disclosed |
| 2022 | Nothing disclosed |
| 2023 | Horizon, consultant Alexion, consultant |
Taher S. Valika, MD
| 2021 | Save My Scope Inc, chief medical officer |
Ruth Ann Vleugels, MD, MPH, MBA
| 2021 | Pfizer, principal investigator for a clinical trial |
Raymond Y. Wang, MD
| 2021 | Biomarin Pharmaceutical, speaking engagement, discontinued Jul 2019 Biomarin Pharmaceutical, advisory committee, discontinued Sep 2019 RegenxBio, advisory committee, discontinued May 2020 Takeda Pharmaceutical, advisory committee, discontinued Aug 2020 Ultragenyx Pharmaceutical, webinar, discontinued Nov 2020 Inventiva Pharmaceutical, advisory committee, discontinued Dec 2020 Neurogene, advisory committee, discontinued Nov 2020 Denali Therapeutics, drug monitoring committee |
| 2022 | Biomarin, ad hoc advisory board, discontinued Oct 2021 Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021 Sio Gene Therapies, consultant, discontinued Nov 2021 Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021 Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021 Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021 Ultragenyx, speaker, discontinued Nov 2020 Neurogene, ad hoc advisory board, discontinued Oct 2020 Regenxbio, ad hoc advisory board, discontinued Apr 2020 |
| 2023 | RegenxBio, consultant Takeda Pharmaceutical, advisory committee, discontinued 2022 Denali, drug safety monitoring board |
Sharmeel K. Wasan, MD
| 2021 | Pfizer, grant support |
| 2022 | Nothing disclosed |
| 2023 | Nothing disclosed |
All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.
Disclosure of Commercial Support
No commercial support was received for this activity.
Medium or Combination of Media Used
This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.
Estimated Time to Complete the Educational Activity
One hour for every 6 questions answered correctly.
Bibliography
Each clinical vignette includes citations and references.
Contact Information
For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free (within the USA and Canada) or +1-781-434-7998.
Policy on Privacy and Confidentiality
Read our Privacy Policy.
Copyright
Copyright information can be found in the NEJM Group Terms of Use.
ABIM Policy
Participant data is governed by ABIM’s Confidentiality Policy and submitted to the ABIM using the ACCME PARS system. Identifiable patient data shall not be provided to ACCME or ABIM by any organization or participant.
Public Information About Providers of MOC Activities
The following information, provided to ACCME by the provider, is considered public information, and therefore may be released by ABIM and/or ACCME.
- Activity title
- Activity type
- Accredited provider name
- Accredited provider contact information (including phone number and website address)
- Joint provider name (if applicable)
- Activity date (start date, in the case of a multi-day live activity or enduring material activity)
- Specialty(ies) activity addresses
- Maximum allowable MOC points and patient safety credit awarded
The following information will be made available in physicians’ MOC history reports located in the secure physician login area of ABIM’s website:
- Activity title
- MOC point value, including patient safety credit, if applicable
- Activity completion date